Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
The NIH Catalyst: A Publication About NIH Intramural Research

National Institutes of Health • Office of the Director | Volume 20 Issue 5 • September–October 2012

Of Monkeys, Mice, and Men

The Promise of Hematopoietic Stem Cells

By HEATHER DOLAN

Cynthia Dunbar means business. Monkey business, that is. Dunbar, who heads the Laboratory of Molecular Hematopoiesis in the National Heart, Lung, and Blood Institute (NHLBI), is investigating human hematopoietic stem cells (HSCs), the precursors to all blood cell types. As it turns out, rhesus monkey (Macaca mulatta) and human HSCs are very similar.

Every year, between 45,000 and 50,000 people worldwide receive HSC transplants to treat life-threatening hematologic diseases, disorders that affect blood cells. “Most of the major advances in biomedicine have been based on hematologic diseases,” said Dunbar. “The first genetic disorder that was described and understood was sickle cell anemia,” a disease in which deformed red blood cells deliver less oxygen to the body’s tissues. Likewise, blood-related cancers as well as immune, metabolic, and red blood cell disorders caused by defective HSCs can be treated by transplantation of normal HSCs.

 Cynthia Dunbar in her lab

Susan Wong, NHLBI

Cynthia Dunbar, head of NHLBI’s Laboratory of Molecular Hematopoiesis, uses primate models to develop hematopoietic stem cell gene therapy approaches that have been successfully transferred to humans in clinical trials.

Dunbar first came to NIH in 1987 as a postdoctoral fellow in Art Nienhuis’s laboratory in NHLBI and worked on developing gene therapies to correct mouse models of hematologic diseases. In the gene therapy she employed, viral vectors deliver a functional gene into disease-stricken target stem and progenitor cells. The therapeutic gene becomes integrated into the host cells’ DNA and produces the missing or defective protein in all daughter cells. Nienhuis’s group successfully developed gene therapy vectors and methods to modify mouse HSCs and developed models for HSC disorders such as leukemia and other diseases.

By 1992, Dunbar and Nienhuis moved the gene therapies into human clinical trials, but the human patients did not respond in the same way as the mice. Less than 0.1 percent of corrected HSCs were found in the patient’s bloodstream long-term. “At that point we realized that mice were not people and it was time to find a more relevant model,” said Dunbar during her Clinical Center Grand Rounds Lecture on June 13, 2012.

And that’s why Nienhuis and Dunbar, quite literally, began monkeyin’ around in earnest. In the late 1980s, they had begun to develop a model to transplant HSCs into rhesus monkeys. “Antibodies, cytokines, and other critical reagents cross-react between human and rhesus [monkey] cells,” said Dunbar. “So you can directly use what you work out in the lab with rhesus [monkeys] and translate it into human clinical trials.”

But Nienhuis was initially hesitant to let Dunbar work in the rhesus macaque facility when she was a postdoc. “He didn’t think I should work on the primates because he didn’t think women should go into the building alone at night,” Dunbar recalled. “It was a different time.” However in 1993, when Nienhuis left NIH to become the chief executive officer of St. Jude Children’s Research Hospital (Memphis, Tenn.), Dunbar inherited the rhesus macaque facility. She relied on the critical knowledge and expertise of Robert Donahue, the veterinarian Nienhuis had recruited in 1990 to develop the primate model.

At first, just keeping the monkeys alive was a challenge. “Only half the animals would survive the [HSC] transplant,” said Dunbar. “But by the mid-1990s, it was rare to lose an animal from transplant complications.” Today, her laboratory uses genetic marking techniques as well as new imaging modalities to track, in monkeys, the output from individual HSCs, how long they last, and what blood cell lineages they contribute to. Dunbar’s laboratory used the primate model to develop HSC gene therapy approaches that have been successfully transferred to humans in several clinical trials. In 2000, 11 pediatric patients at Necker Hospital (Paris) received gene therapy for X-linked severe combined immunodeficiency (X-SCID), a disorder that affects T cells. Two years later, nine of the patients were seemingly cured and had restored their T cell counts. (NEJM 346:1185–1193, 2002) But by 2003, five of the cured patients had developed leukemia. Somehow, the therapies were curing X-SCID while simultaneously turning on oncogenes.

Dunbar’s group is still battling the gene therapy toxicity problem. “We must work out a way to get the benefits of an integrating vector without the risk of it turning on cancer-causing genes,” she said.

While the toxicity issues are being worked out, gene therapy remains a promising treatment for patients who would otherwise have no hope of surviving. “If you’re treating leukemia or X-SCID, taking those risks is probably worth it,” said Dunbar. It provides “some chance that these patients are surviving beyond age two.”

This page was last updated on Friday, April 29, 2022

  • Issue Overview
  • Features
    • An NIH Research Dynasty in Building 3
    • Clinical Center Welcomes Extramural Investigators
    • A Pain-staking Intramural Research Program
    • Of Monkeys, Mice, and Men
    • NIBIB 10th Anniversary
    • PI Profile Pages Go Live
    • Subra Suresh: At the Interface of Engineering and Biology
  • Departments
    • From the Deputy Director for Intramural Research
    • Commentary
    • Colleagues: Recently Tenured
    • Research Briefs
    • News You Can Use
    • The Training Page
    • News Briefs
    • The SIG Beat
    • Photographic Moment
    • Announcements
  • Issue Contents
  • Download this issue as a PDF

Catalyst menu

  • Current Issue
  • Previous Issues
  • About The NIH Catalyst
  • Contact The NIH Catalyst
  • Share Your Story
  • NIH Abbreviations

Subscribe Today!

Subscribe to The NIH Catalyst Newsletter and receive email updates.

Subscribe

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search